echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > J Aller Cl Imm-Pract: Eosinophilia is associated with improved COVID-19 outcomes in inhaled corticosteroid-treated patients

    J Aller Cl Imm-Pract: Eosinophilia is associated with improved COVID-19 outcomes in inhaled corticosteroid-treated patients

    • Last Update: 2022-02-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In addition to their pro-inflammatory effects, eosinophils also have antiviral properties


    COVID-19

    The researchers analyzed data from the Cleveland Clinic COVID-19 Research Registry (April 1, 2020 to March 31, 2021)


    Of the 46,397 patients included in the final analysis, 19,506 patients had pre-existing eosinophilia (>0.


    Among iCS-treated patients, adjusted analysis found eosinophilia associated with hospitalization (OR [95%CI]: 0.


    Thus, the association between eosinophilia and improved outcomes in COVID-19 patients depends on iCS


    The association between eosinophilia and improved outcomes in COVID-19 patients depends on iCS


    Original source:

    Joe G.


    Eosinophilia is associated with improved COVID-19 outcomes in inhaled corticosteroids-treated

    patients
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.